Otsuka scores PhIII win for another Astex drug; GSK expands Nucala use in asthma
→ Otsuka has some good news to report on the other drug that it obtained in the $886 million acquisition of Astex Pharmaceuticals. ASTX727 combines …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
